Journal Article Review Epublish 11 citations
PubMed: 38534206 DOI: 10.3390/antib13010016
Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development.
Antibodies (Basel) 13(1)
Authors: Tsvetelina Velikova, Metodija Sekulovski, Monika Peshevska-Sekulovska
Affiliations
- Medical Faculty, Sofia University St. Kliment Ohridski, 1 Kozyak Str. 1407 Sofia, Bulgaria.
- Department of Anesthesiology and Intensive Care, University Hospital Lozenetz, 1 Kozyak Str. 1407 Sofia, Bulgaria.
- Department of Gastroenterology, University Hospital Lozenetz, 1407 Sofia, Bulgaria.
Abstract
Many patients with inflammatory bowel disease (IBD) experience a loss of effectiveness to biologic therapy (i.e., anti-TNF therapy, etc.). Therefore, in addition to the adverse effects of the treatment, these patients also face failure to achieve and maintain remission. Immunogenicity, the process of production of antibodies to biological agents, is fundamental to the evolution of loss of response to treatment in IBD patients. The presence of these antibodies in patients is linked to decreased serum drug levels and inhibited biological activity. However, immunogenicity rates exhibit significant variability across inflammatory disease states, immunoassay formats, and time periods. In this review, we aimed to elucidate the immunogenicity and immune mechanisms of antibody formation to biologics, the loss of therapy response, clinical results of biological treatment for IBD from systematic reviews and meta-analyses, as well as to summarize the most recent strategies for overcoming immunogenicity and approaches for managing treatment failure in IBD.
MeSH
Antibodies, Inflammatory Bowel Diseases, Pharmaceutical Preparations, Therapeutics, Biological Therapy, Safety
Cited by
- Enterocutaneous Fistula in a Patient with Crohn's Disease After Internalization of a Foreign Body into the Gastrointestinal Tract. J Clin Med, 2025
- Anti-Drug Antibody Response to Therapeutic Antibodies and Potential Mitigation Strategies. Biomedicines, 2025
- Secondary Non-Response to Biologic Treatment in Patients with Severe Asthma. J Asthma Allergy, 2025
- A Randomized Controlled Pilot Study Evaluating the Safety and Efficacy of Nifuroxazide in Patients with Ulcerative Colitis. Drug Des Devel Ther, 2025
- A practical approach to positioning therapies in ulcerative colitis. J Can Assoc Gastroenterol, 2025
- Nanobodies: From Discovery to AI-Driven Design. Biology (Basel), 2025
- Efficacy of Serum BDNF for the Evaluation of Depressive Neurological Symptoms in Patients with Refractory Ulcerative Colitis. J Clin Med, 2025
- Effectiveness of Frequently Used TNF Inhibitors vs. Conventional Immunosuppressive Therapies for Noninfectious Uveitis. Ocul Immunol Inflamm, 2025
- Inflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies. Cureus, 2025